AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed further research with tab-cel, including study 205.
The phase 3 ALLELE study (NCT03394365) has demonstrated tablecleucel’s (tab-cel; Atara Biotherapeutics) efficacy in patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD).1,2
Data from the study showed clinically meaningful improvements in overall response rate (ORR) with promising overall survival (OS) rates and were presented at the American Society of Hematology 2021 Meeting, December 11-14, by Susan Prockop, MD, pediatric oncologist/hematologist, program director, Clinical and Translational Research, Boston Children’s Hospital. (Prockop is formerly of Memorial Sloan Kettering [MSK], an ALLELE trial site).
Tab-cel is also being evaluated in the phase 2 ATA129-EBV-205 study (NCT04554914) in a variety of immunodeficiency associated, EBV-driven conditions, as well as liquid tumors and solid tumors.
GeneTherapyLive spoke with AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, to learn more about further research being conducted with tab-cel. He stressed the importance of tab-cel being the first allogeneic T-cell immunotherapy to be submitted to a regulatory agency
For more coverage of ASH 2021, click here.